References in periodicals archive ?
First, adjustment of antiplatelet therapy using PFT was not mandated by the protocol but was instead at the discretion of the operator.
Apixaban showed a trend toward a reduction in ischemic events in patients with ACS but also demonstrated an increased bleeding risk particularly in those taking dual antiplatelet therapy (39).
High-risk cardiovascular patients on dual therapy may benefit from endoscopic therapy Collaboration between the cardiologist and endoscopist is important to assess the risk of bleeding against the risk of thrombosis in regard to the timing of antiplatelet therapy cessation.
The importance of keeping patients with drug-eluting stents on dual antiplatelet therapy has been vastly underestimated, according to new warnings about the risk of late thrombosis issued by the Food and Drug Administration and several professional societies.
an interventional cardiologist at the Brigham and Women's Hospital and Harvard Medical School in Boston, MA and chief scientific officer of Harvard Clinical Research Institute, said, "The global scope of the DAPT Study demonstrates the significant interest on the part of clinicians worldwide in answering this critical question on the benefits and the risks associated with prolonged dual antiplatelet therapy beyond one year following a stent procedure.
Of patients with early stent thrombosis, 89% were on dual antiplatelet therapy at the time, compared with 22% of those with late stent thrombosis.
Equally important to note is that late stent thrombosis is improbable because the stent has bioresorbed, and therefore extended antiplatelet therapy is unnecessary with this approach.
Clinical Studies Will Be Featured in HEALING Symposium and Scientific Sessions; Data Support the Use of Genous Stent in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable
Worldwide COGENT-1 Study of CGT-2168 Expands to Europe; Focus on Reducing Gastrointestinal Side Effects of Antiplatelet Therapy
LOS ANGELES -- The rate of small-bowel findings on capsule endoscopy was the same whether or not patients were on anticoagulation or antiplatelet therapy, results from a single-center study showed.
First European Patients Enrolled into Four-year, Public Health Study to Investigate the Duration of Dual Antiplatelet Therapy Following Drug-eluting Stent Procedures -
Up to one in three individuals may not be responding adequately to their antiplatelet therapy.
Although results of large-scale, randomized control trials are awaited to make more definitive conclusions, I believe Genous will be a good treatment option for patients who cannot undergo long-term dual antiplatelet therapy or patients who have increased risk of thrombotic events.
CHARISMA was an ambitious 15,063-patient randomized trial aimed at expanding the indications for dual antiplatelet therapy with clopidogrel (Plavix) and low-dose aspirin.
0 Special considerations with antiplatelet therapy.